Photodynamic therapy-induced AP-1 survival signaling (WP3611)
Homo sapiens
Photodynamic therapy may induce an acute stress response mediated by mitogen-activated protein kinase kinase kinase 5 (MAP3K5), its downstream MAPKs that target c-Jun N-terminal kinase (JNK, MAPK8) and p38MAPK, and the transcription factors of the activator protein 1 (AP-1) family.
For a description of pathway objects, see the WikiPathways Legend.
Authors
Ruud Weijer , Kristina Hanspers , Friederike Ehrhart , Alex Pico , and Eric WeitzActivity
Discuss this pathway
Check for ongoing discussions or start your own.
Cited In
- Systems biology approach reveals a common molecular basis for COVID-19 and non-alcoholic fatty liver disease (NAFLD) (2022).
- A Practical Strategy for Exploring the Pharmacological Mechanism of Luteolin Against COVID-19/Asthma Comorbidity: Findings of System Pharmacology and Bioinformatics Analysis (2024).
- Serum extracellular vesicle microRNAs as potential biomarkers to predict pembrolizumab response and prognosis in metastatic non-small cell lung cancer patients (2025).
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Organisms
Homo sapiensCommunities
Annotations
Disease Ontology
cancerPathway Ontology
altered regulatory pathway| Label | Type | Compact URI | Comment |
|---|---|---|---|
| TRAF6 | GeneProduct | ncbigene:7189 | |
| PDGFRA | GeneProduct | ncbigene:5156 | |
| MAPK11 | GeneProduct | ncbigene:5600 | |
| JUNB | GeneProduct | ncbigene:3726 | |
| IL6 | GeneProduct | ncbigene:3569 | |
| HSP90AA1 | GeneProduct | ncbigene:3320 | |
| IL2 | GeneProduct | ncbigene:3558 | |
| TRAF5 | GeneProduct | ncbigene:7188 | |
| IFNG | GeneProduct | ncbigene:3458 | |
| TNFSF10 | GeneProduct | ncbigene:8743 | |
| TNF | GeneProduct | ncbigene:7124 | |
| CCND1 | GeneProduct | ncbigene:595 | |
| TRAF2 | GeneProduct | ncbigene:7186 | |
| MAPK13 | GeneProduct | ncbigene:5603 | |
| FOS | GeneProduct | ncbigene:2353 | |
| MMP2 | GeneProduct | ncbigene:4313 | |
| MAPK12 | GeneProduct | ncbigene:6300 | |
| MAP2K7 | GeneProduct | ncbigene:5609 | |
| MAPK14 | GeneProduct | ncbigene:1432 | |
| MAP2K3 | GeneProduct | ncbigene:5606 | |
| MAP3K5 | GeneProduct | ncbigene:4217 | |
| MAP2K4 | GeneProduct | ncbigene:6416 | |
| MAP2K6 | GeneProduct | ncbigene:5608 | |
| TNFRSF1A | GeneProduct | ncbigene:7132 | |
| CCNA2 | GeneProduct | ncbigene:890 | |
| CCNE1 | GeneProduct | ncbigene:898 | |
| EGFR | GeneProduct | ncbigene:1956 | |
| HBEGF | GeneProduct | ncbigene:1839 | |
| FGF7 | GeneProduct | ncbigene:2252 | |
| FASLG | GeneProduct | ncbigene:356 | |
| FAS | GeneProduct | ncbigene:355 | |
| RB1 | GeneProduct | ncbigene:5925 | |
| TP53 | GeneProduct | ncbigene:7157 | |
| CDKN1A | GeneProduct | ncbigene:1026 | |
| BCL2 | GeneProduct | ncbigene:596 | |
| BCL2L1 | GeneProduct | ncbigene:598 | |
| BCL2L11 | GeneProduct | ncbigene:10018 | |
| BCL3 | GeneProduct | ncbigene:602 | |
| CDKN2A | GeneProduct | ncbigene:1029 | |
| BID | GeneProduct | ncbigene:637 | |
| CFLAR | GeneProduct | ncbigene:8837 | |
| NFE2L2 | GeneProduct | ncbigene:4780 | |
| BAK1 | GeneProduct | ncbigene:578 | |
| BAX | GeneProduct | ncbigene:581 | |
| MCL1 | GeneProduct | ncbigene:4170 | |
| BMF | GeneProduct | ncbigene:90427 | |
| ELK1 | GeneProduct | ncbigene:2002 | |
| JUN | GeneProduct | ncbigene:3725 | |
| ATF2 | GeneProduct | ncbigene:1386 | |
| MAPK8 | GeneProduct | ncbigene:5599 |
References
- Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. Broekgaarden M, Weijer R, van Gulik TM, Hamblin MR, Heger M. Cancer Metastasis Rev. 2015 Dec;34(4):643–90. PubMed Europe PMC Scholia
- Low-power photodynamic therapy induces survival signaling in perihilar cholangiocarcinoma cells. Weijer R, Broekgaarden M, van Golen RF, Bulle E, Nieuwenhuis E, Jongejan A, et al. BMC Cancer. 2015 Dec 26;15:1014. PubMed Europe PMC Scholia